1. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Blechacz B, Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48(1):308-321.
3. Rizvi S, Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013, 145(6):1215-1229.
4. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM: Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg 2014.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
6. Fridman WH, Pages F, Sautes-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12(4):298-306.
7. Zhou SL, Yin D, Hu ZQ, Luo CB, Zhou ZJ, Xin HY, Yang XR, Shi YH, Wang Z, Huang XW et al: A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. Hepatology 2019, 70(4):1214-1230.
8. Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang XW, Zhu AX: Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology 2018.
9. Sirica AE, Gores GJ: Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 2014, 59(6):2397-2402.
10. Swiecki M, Colonna M: Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010, 234(1):142-162.
11. Lande R, Gilliet M: Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010, 1183:89-103.
12. Swiecki M, Colonna M: The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015, 15(8):471-485.
13. Vermi W, Soncini M, Melocchi L, Sozzani S, Facchetti F: Plasmacytoid dendritic cells and cancer. J Leukoc Biol 2011, 90(4):681-690.
14. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C et al: Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004, 10(22):7466-7474.
15. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A et al: Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011, 71(16):5423-5434.
16. Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A, Ponnazhagan S: Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 2012, 189(9):4258-4265.
17. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C et al: Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16(4):309-323.
18. Wittekind C: [Pitfalls in the classification of liver tumors]. Pathologe 2006, 27(4):289-293.
19. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA: AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018, 67(1):358-380.
20. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J: Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology 2016, 150(7):1646-1658 e1617.
21. Zhou SL, Hu ZQ, Zhou ZJ, Dai Z, Wang Z, Cao Y, Fan J, Huang XW, Zhou J: miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology 2016, 63(5):1560-1575.
22. Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z, Fan J, Dai Z, Zhou J: CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling. Cancer Lett 2015, 358(2):124-135.
23. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
24. Boiocchi L, Lonardi S, Vermi W, Fisogni S, Facchetti F: BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood 2013, 122(2):296-297.
25. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Gunther G, Johnston I, Lanzavecchia A, Nagasaka T et al: BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001, 194(12):1823-1834.
26. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995-2004.
27. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10(2):99-111.
28. Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9(4):274-284.
29. Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19(11):1423-1437.
30. Lin A, Schildknecht A, Nguyen LT, Ohashi PS: Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett 2010, 127(2):77-84.
31. Matta BM, Castellaneta A, Thomson AW: Tolerogenic plasmacytoid DC. Eur J Immunol 2010, 40(10):2667-2676.
32. Demoulin S, Herfs M, Delvenne P, Hubert P: Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 2013, 93(3):343-352.
33. Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G: The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 2017, 14(12):717-734.